No products in the cart.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
1. There is a 71% lower risk of disease progression or death in the nirogacestat group than in the placebo...
Dermatology
Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated,...
Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2....
Difelikefalin reduces pruritus in adults with notalgia paresthetica
1. In this randomized controlled trial, difelikefalin reduced pruritus intensity in patients with notalgia paresthetica over eight weeks of treatment...
Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at...
Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
1. At week 16, all rocatinlimab groups reported significant improvements in eczema severity. 2. Most treatment-related adverse events were mild-to-moderate,...
Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections...
Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa
1. Topical gene therapy beremagene geperpavec (B-VEC) was superior to placebo in achieving complete wound healing in patients with dystrophic...
Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had...
Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.